ESTRO 2025 - Abstract Book

S383

Brachytherapy - Urology

ESTRO 2025

Conclusion: Salvage HDR-BT is a safe and effective treatment for locally relapsed prostate cancer patients with an acceptable G3-G4 toxicity profile. It should be considered a preferred therapeutic option over chronic ADT standard treatment.

Keywords: Salvage, HDR, Recurrent

References: Corkum MT, Buyyounouski MK, Chang AJ, et al. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study. Radiother Oncol. 2023;184:109672. doi:10.1016/j.radonc.2023.109672. Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II 2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164-182. doi:10.1016/j.eururo.2024.04.010. Valle LF, Lehrer EJ, Markovic D, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021;80(3):280-292. doi:10.1016/j.eururo.2020.11.010.

2534

Digital Poster Spanish Salvage Prostate Brachytherapy (RESPRO STUDY) in the NGI era.

Patricia Willisch Santamaría 1 , Elena Villafranca Iturre 2 , Susana Roldán Ortega 3 , David Büsher García 4 , Silvia Rodríguez Villalba 5 , Alai Goñi Ramírez 6 , Juan Antonio Camús Martínez 7 , Teresa Muñoz Migueláñez 8 , Luis Sopeña Sainz 9 , Ana Alonso García 10